Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
August 2013, Vol 6 ADA 2013 Highlights
Intensive Treatment Early in Type 1 Diabetes Produces Substantial Long-Term Benefits
Mary Mosley
Read More
New Data Show Ranolazine Most Effective Antianginal Agent for Patients with Type 2 Diabetes and HbA1c >7%
Wayne Kuznar
Read More
Emerging Therapies
Albiglutide, a GLP-1 Receptor Agonist, Effective in Various Treatment Scenarios in Patients with Type 2 Diabetes
Mary Mosley
Read More
Financial Incentives Can Promote Maintenance of Weight Loss, a Major Factor in Diabetes
Wayne Kuznar
Read More
Costs of Diabetes-Related Complications Reduced with Canagliflozin Monotherapy
Mary Mosley
Read More
Resource Utilization and Costs: Comparing Saxagliptin and Sitagliptin
Mary Mosley
Read More
Substantial Costs for Diabetes Are Consumed by the Diabetic Foot and Arthritis
Mary Mosley
Read More
Specialized Team Approach and Education Improve Care, Save Money in Diabetes
Mary Mosley
Read More
Future of Healthcare Reform: Expect New Payment and Delivery Models
Wayne Kuznar
Read More
Drug Updates
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Read More
1
2
Page 1 of 2
Results 1 - 10 of 19